• Dry Cracked Skin
  • Impetigo
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Delving Into Fall Clinical 2023 With Del Rosso

News
Article

One of the many minds behind innovative Fall Clinical Dermatology sessions gives a sneak peek of the top 5 things to look forward to during this year's meeting.

The 2023 Fall Clinical Dermatology Conference in Las Vegas, Nevada will be a full of the latest advancements and insights from October 19-22. James Del Rosso, DO, adjunct clinical professor of dermatology at Touro University College of Osteopathic Medicine, and co-director and co-founder of the Fall and Winter Clinical dermatology conferences, shed light on the top 5 things to look forward to this week.

The Great Debate: Monoclonal Antibodies Versus Janus Kinase Inhibitors

Del Rosso introduces an exciting addition to the conference—a debate format with Alexandra Golant, MD, from Mount Sinai. They'll delve into the merits and potential drawbacks of monoclonal antibodies and JAK inhibitors on a case-by-case basis. This promises to be both informative and engaging, as these experts challenge each other's perspectives.

“We both know these therapies and utilize these therapies,” Del Rosso explained. “They both have their merits, and they both have potential drawbacks. It's not like we only believe in 1 side or the other.”

In-Depth Medication Insights

In the 2-part session “What’s New in the Medicine Chest,” Del Rosso will emphasize the importance of delving into existing and upcoming medications and the data backing their safety and efficacy. He sifted through the wealth of new data available, distilling it into clinically meaningful insights. Attendees will leave with a comprehensive understanding of the latest oral, topical, and injectable treatments.

“One day one might be a better choice for you, the next day, it might be another and that's the beauty of having these therapies, but you have to learn them and focus on each of them individually,” he said.

Focus on Mechanisms of Action and Therapies

Del Rosso believes understanding mechanisms of action, and that will be a focus during all of the sessions he will present in. With a particular focus on medical dermatology, he highlights the innovations in treatments for various conditions, such as alopecia areata, hidradenitis suppurativa, psoriasis, atopic dermatitis, and acne.

“There's new data on treatments that have existed, and new data on treatments that should be coming along pretty soon. So, it's exciting,” he shares. “I think it's really important to be looking at with a variety of different these different disease states to really keep an open mind and there's a variety of different approved therapies.”

New Data on Approved Therapies

Del Rosso stresses the importance of staying updated on both established and emerging treatments. He sheds light on the nuances between different drugs within the same mechanistic class, emphasizing that each approved therapy has its unique benefits for specific patients.

“Acne has several improvements in both the medical dermatology and even in the device space. We can't forget that at this meeting, there's cosmetic dermatology, but my focus is on medical dermatology,” he explained. “I'll be covering a variety of different topical therapies and new information about ones that are already out there. We have non-steroidal treatments, but we still have some corticosteroid agents that are different than some of the others which we'll be going over. Topical JAK inhibitors are expanding in use, not only for atopic dermatitis, but vitiligo, and even some new areas being looked at.”

Exploring Cutting-Edge Therapies

Del Rosso introduces attendees to exciting advancements, like OX-40 signaling, which has piqued his interest. “OX-40 pathway activation promotes differentiation of activated effector T cells into memory T cells and amplifies and sustains the T cell response, all of which are essential to driving atopic dermatitis pathogenesis,” his presentation highlights. This innovation holds promise for chronic disease management, going beyond controlling flares to address the underlying memory process.

Additionally, a novel approach to case discussions will be offered by a distinguished faculty including Linda Stein Gold, Julie Harper, and Sandra Lee (aka Dr. Pimple Popper). These experts will dissect cases, providing valuable insights into optimal therapeutic approaches.

The 2023 Fall Clinical Dermatology Conference is set to be the most comprehensive yet, with expanded activities and an esteemed faculty of over 200 contributors. With Del Rosso's extensive experience and commitment to making complex information clinically relevant, attendees can expect to leave the conference with a wealth of practical knowledge and a deeper understanding of the latest developments in dermatology.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.